Table 1 Clinical and biochemical characteristics of NAFLD Compared with Control Subjects.
From: Elevated endotoxin levels in non-alcoholic fatty liver disease
| Â | NAFLD | Controls | P-value |
|---|---|---|---|
Age (yrs) | 49.1 ± 12.6 | 44.6 ± 9.9 | NS |
BMI (kg/m 2 ) | 34.0 ± 6.0 | 26.4 ± 4.5 | 0.0001 |
Endotoxin #: (EU/mL) | 10.6(7.8, 14.8) | 3.9(3.2, 5.2) | 0.0001 |
Fatty Liver # | 11.7(7.3, 15.6) | n/a | 0.0001 |
NASH # | 10.5(8.0, 14.0) | n/a | 0.0001 |
Cirrhosis # | 7.1(5.2, 11.2) | n/a | 0.01 |
Insulin # (μU/mL) | 18.5(10.3, 28.8) | 12.9(10.6, 16.0) | 0.001 |
Glucose # (mmol/L) | 5.5(4.8, 6.5) | 5.3(4.9, 6.2) | NS |
HOMA-IR # | 4.2(2.5, 7.5) | 3.1(2.4, 4.1) | 0.001 |
TNF-α # (pg/mL) | 5.8(4.5, 8.1) | 11.2(9.5, 12.2) | 0.0001 |
sCD14 # (ng/mL) | 1623(1370, 2013) | 1431.3 ± (1244, 1827) | NS |
sTNFRII # (pg/mL) | 2229.2(1865.6, 2879.9) | 2253.2(1900.4, 2536.5) | NS |